Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors

  • Carlomagno F
  • Guida T
  • Anaganti S
 et al. 
  • 38


    Mendeley users who have this article in their library.
  • 151


    Citations of this article.


We have recently demonstrated that the pyrazolopyrimidines PP1 and PP2 and the 4-anilinoquinazoline ZD6474 display a strong inhibitory activity (IC(50)< or =100 nM) towards constitutively active oncogenic RET kinases. Here, we show that most oncogenic MEN2-associated RET kinase mutants are highly susceptible to PP1, PP2 and ZD6474 inhibition. In contrast, MEN2-associated swap of bulky hydrophobic leucine or methionine residues for valine 804 in the RET kinase domain causes resistance to the three compounds. Substitution of valine 804 with the small amino- acid glycine renders the RET kinase even more susceptible to inhibition (ZD6474 IC(50): 20 nM) than the wild-type kinase. Our data identify valine 804 of RET as a structural determinant mediating resistance to pyrazolopyrimidines and 4-anilinoquinazolines.

Author-supplied keywords

  • MEN2
  • RET
  • Thyroid
  • Tyrosine kinase inhibitors

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Francesca Carlomagno

  • Teresa Guida

  • Suresh Anaganti

  • Giancarlo Vecchio

  • Alfredo Fusco

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free